You may have heard about a recent health scare that turned out to be epididymitis — a common, non-cancerous inflammation near the testicle. But it raises an important question: when should you actually worry about testicular cancer?
The biggest signs to watch for are a new lump, swelling, a feeling of heaviness, persistent discomfort, or a change in the size or firmness of a testicle. Most changes are not cancer, but any new abnormality should be checked by a healthcare professional.
What if a diabetes drug could also lower your risk of colon cancer? A massive new study in JAMA Oncology may have found an important clue. Researchers analyzed health records from over one million people with type 2 diabetes who had never taken diabetes medication before. They wanted to see whether GLP-1 drugs like semaglutide or liraglutide were linked to a lower chance of developing colorectal cancer.
Cervical cancer remains one of the most common cancers affecting women worldwide. It is strongly linked to long-term infection with high-risk types of human papillomavirus (HPV), especially HPV16 and HPV18. Vaccination against HPV 16 and HPV 18 are effective in preventing cervical cancer, especially when given in adolescence. However, once cervical cancer occurs, surgery, chemotherapy, and radiation can be effective in early stages, but outcomes are still poor for advanced or recurrent disease.
A 2025 review published in Exploration of Targeted Anti-tumor Therapy highlights how immunotherapy is changing the treatment landscape. By helping the immune system recognize and attack cancer cells, these newer approaches are offering new hope for better outcomes
What is it prescribed for? PENPULIMAB-KCQX is prescribed for adults with a type of head and neck cancer called non-keratinizing nasopharyngeal carcinoma (NPC). This cancer starts in the upper part of the throat, behind the nose. It can be used: With chemotherapy (cisplatin or carboplatin plus gemcitabine) as the first treatment when the cancer has come back...
What if a new drug combo could finally help patients with the toughest breast cancer?
Triple-negative breast cancer, or TNBC, is one of the most aggressive forms of breast cancer. It’s called “triple negative” because the cancer cells lack three common receptors — estrogen, progesterone, and HER2 — that some other breast cancers have. That matters because most targeted therapies work by attaching to one of those receptors. Without them, TNBC doesn’t respond to hormone therapy or HER2-targeted drugs, so doctors often rely on chemotherapy first. TNBC accounts for about 15–20% of breast cancer cases and is especially hard to treat once it spreads.
What is ORSERDU prescribed for? For treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy What is the name of the drug and what does it do? ORSERDU (generic name: elacestrant), pronounced...